N Ortiz-Brüchle1, M Muders2, M Toma2, I Esposito3, A Hartmann4, R Stöhr4, H Reis5, P Wild6, J Köllermann6, F Bremmer7, J Leichsenring8, A Stenzinger8, S Merkelbach-Bruse9, S Kirfel10, S Perner10,11, N Hartmann12, W Roth12, A Jung13, T Kirchner13, K Schwamborn14, N Pfarr14, E Dahl1, R Knüchel1, N T Gaisa15. 1. Institut für Pathologie, Uniklinikum, RWTH Aachen, Pauelsstraße 30, 52074, Aachen, Deutschland. 2. Institut für Pathologie, Universitätsklinikum Bonn, Bonn, Deutschland. 3. Institut für Pathologie, Universitätsklinikum Düsseldorf, Heinrich-Heine Universität, Düsseldorf, Deutschland. 4. Institut für Pathologie, Universitätsklinikum Erlangen, Erlangen, Deutschland. 5. Institut für Pathologie, Universitätsklinikum Essen, Essen, Deutschland. 6. Dr. Senckenbergisches Institut für Pathologie, Frankfurt, Deutschland. 7. Institut für Pathologie, Universitätsklinikum Göttingen, Göttingen, Deutschland. 8. Molekularpathologisches Zentrum, Pathologisches Institut, Universitätsklinikum Heidelberg, Heidelberg, Deutschland. 9. Institut für Pathologie, Uniklinik Köln, Köln, Deutschland. 10. Institut für Pathologie, Universitätsklinikum Lübeck, Lübeck, Deutschland. 11. Pathologie, Forschungszentrum Borstel, Leibniz Lungenzentrum, Borstel, Deutschland. 12. Institut für Pathologie, Universitätsklinikum Mainz, Mainz, Deutschland. 13. Pathologisches Institut, LMU München, München, Deutschland. 14. Institut für Pathologie, TU München, München, Deutschland. 15. Institut für Pathologie, Uniklinikum, RWTH Aachen, Pauelsstraße 30, 52074, Aachen, Deutschland. ngaisa@ukaachen.de.
Abstract
BACKGROUND: Technical advancement and availability of high-throughput analysis has advanced molecular subtyping of most cancers. Thus, new possibilities for precision oncology have emerged. AIM: Therefore, we aimed to collect data regarding availability and use of next generation sequencing (NGS) for urothelial cancer within the uropathology working group of the German Society of Pathology. METHODS: We collected data by questionnaires and additionally asked for sequencing results of bladder cancers in the participating institutions. RESULTS: A total of 13 university-affiliated institutes of pathology took part in the survey. All university institutes offer NGS-based molecular panel diagnostics and provide panels covering between 15 and 170 genes. Altogether, only 20 bladder cancers were sequenced in routine diagnostics and for 10 cancers potential targeted treatment options were available. DISCUSSION: So far, despite availability of NGS diagnostics at university institutes of pathology, only few bladder cancer samples have been sequenced. Based on current data from the molecular subtyping of bladder cancers, we recommend a step-by-step protocol with basic immunohistochemistry analysis and subsequent subtype-dependent analyses, e.g., alterations of the fibroblast growth factor receptors (FGFR) or comprehensive gene panel analyses.
BACKGROUND: Technical advancement and availability of high-throughput analysis has advanced molecular subtyping of most cancers. Thus, new possibilities for precision oncology have emerged. AIM: Therefore, we aimed to collect data regarding availability and use of next generation sequencing (NGS) for urothelial cancer within the uropathology working group of the German Society of Pathology. METHODS: We collected data by questionnaires and additionally asked for sequencing results of bladder cancers in the participating institutions. RESULTS: A total of 13 university-affiliated institutes of pathology took part in the survey. All university institutes offer NGS-based molecular panel diagnostics and provide panels covering between 15 and 170 genes. Altogether, only 20 bladder cancers were sequenced in routine diagnostics and for 10 cancers potential targeted treatment options were available. DISCUSSION: So far, despite availability of NGS diagnostics at university institutes of pathology, only few bladder cancer samples have been sequenced. Based on current data from the molecular subtyping of bladder cancers, we recommend a step-by-step protocol with basic immunohistochemistry analysis and subsequent subtype-dependent analyses, e.g., alterations of the fibroblast growth factor receptors (FGFR) or comprehensive gene panel analyses.
Authors: Yves Allory; Willemien Beukers; Ana Sagrera; Marta Flández; Miriam Marqués; Mirari Márquez; Kirstin A van der Keur; Lars Dyrskjot; Irene Lurkin; Marcel Vermeij; Alfredo Carrato; Josep Lloreta; José A Lorente; Enrique Carrillo-de Santa Pau; Roy G Masius; Manolis Kogevinas; Ewout W Steyerberg; Angela A G van Tilborg; Cheno Abas; Torben F Orntoft; Tahlita C M Zuiverloon; Núria Malats; Ellen C Zwarthoff; Francisco X Real Journal: Eur Urol Date: 2013-09-07 Impact factor: 20.096
Authors: Lucia Nogova; Lecia V Sequist; Jose Manuel Perez Garcia; Fabrice Andre; Jean-Pierre Delord; Manuel Hidalgo; Jan H M Schellens; Philippe A Cassier; D Ross Camidge; Martin Schuler; Ulka Vaishampayan; Howard Burris; G Gary Tian; Mario Campone; Zev A Wainberg; Wan-Teck Lim; Patricia LoRusso; Geoffrey I Shapiro; Katie Parker; Xueying Chen; Somesh Choudhury; Francois Ringeisen; Diana Graus-Porta; Dale Porter; Randi Isaacs; Reinhard Buettner; Jürgen Wolf Journal: J Clin Oncol Date: 2016-11-21 Impact factor: 44.544
Authors: Woonyoung Choi; Sima Porten; Seungchan Kim; Daniel Willis; Elizabeth R Plimack; Jean Hoffman-Censits; Beat Roth; Tiewei Cheng; Mai Tran; I-Ling Lee; Jonathan Melquist; Jolanta Bondaruk; Tadeusz Majewski; Shizhen Zhang; Shanna Pretzsch; Keith Baggerly; Arlene Siefker-Radtke; Bogdan Czerniak; Colin P N Dinney; David J McConkey Journal: Cancer Cell Date: 2014-02-10 Impact factor: 31.743
Authors: Maximilian Burger; Madelon N M van der Aa; Johanna M M van Oers; Anke Brinkmann; Theodorus H van der Kwast; Ewout C Steyerberg; Robert Stoehr; Wim J Kirkels; Stefan Denzinger; Peter J Wild; Wolf F Wieland; Ferdinand Hofstaedter; Arndt Hartmann; Ellen C Zwarthoff Journal: Eur Urol Date: 2007-12-26 Impact factor: 20.096
Authors: A Gordon Robertson; Jaegil Kim; Hikmat Al-Ahmadie; Joaquim Bellmunt; Guangwu Guo; Andrew D Cherniack; Toshinori Hinoue; Peter W Laird; Katherine A Hoadley; Rehan Akbani; Mauro A A Castro; Ewan A Gibb; Rupa S Kanchi; Dmitry A Gordenin; Sachet A Shukla; Francisco Sanchez-Vega; Donna E Hansel; Bogdan A Czerniak; Victor E Reuter; Xiaoping Su; Benilton de Sa Carvalho; Vinicius S Chagas; Karen L Mungall; Sara Sadeghi; Chandra Sekhar Pedamallu; Yiling Lu; Leszek J Klimczak; Jiexin Zhang; Caleb Choo; Akinyemi I Ojesina; Susan Bullman; Kristen M Leraas; Tara M Lichtenberg; Catherine J Wu; Nicholaus Schultz; Gad Getz; Matthew Meyerson; Gordon B Mills; David J McConkey; John N Weinstein; David J Kwiatkowski; Seth P Lerner Journal: Cell Date: 2017-10-05 Impact factor: 41.582
Authors: Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm Journal: Genet Med Date: 2015-03-05 Impact factor: 8.822
Authors: Sharon E Plon; Diana M Eccles; Douglas Easton; William D Foulkes; Maurizio Genuardi; Marc S Greenblatt; Frans B L Hogervorst; Nicoline Hoogerbrugge; Amanda B Spurdle; Sean V Tavtigian Journal: Hum Mutat Date: 2008-11 Impact factor: 4.878
Authors: Seth P Lerner; David J McConkey; Katherine A Hoadley; Keith S Chan; William Y Kim; François Radvanyi; Mattias Höglund; Francisco X Real Journal: Bladder Cancer Date: 2016-01-07